|
1
|
Shaib Y and El-Serag HB: The epidemiology
of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Patel N and Benipal B: Incidence of
Cholangiocarcinoma in the USA from 2001 to 2015: A US Cancer
Statistics Analysis of 50 States. Cureus. 11:e39622019.PubMed/NCBI
|
|
3
|
Yao KJ, Jabbour S, Parekh N, Lin Y and
Moss RA: Increasing mortality in the United States from
cholangiocarcinoma: An analysis of the National Center for Health
Statistics Database. BMC Gastroenterol. 16:1172016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mavros MN, Economopoulos KP, Alexiou VG
and Pawlik TM: Treatment and Prognosis for Patients With
Intrahepatic Cholangiocarcinoma: Systematic Review and
Meta-analysis. JAMA Surg. 149:565–574. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arrington AK, Nelson RA, Falor A, Luu C,
Wiatrek RL, Fakih M, Singh G and Kim J: Impact of medical and
surgical intervention on survival in patients with
cholangiocarcinoma. World J Gastrointest Surg. 5:178–186. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, et al: ABC-02 Trial Investigators: Cisplatin plus gemcitabine
versus gemcitabine for biliary tract cancer. N Engl J Med.
362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park JO, Oh DY, Hsu C, Chen JS, Chen LT,
Orlando M, Kim JS and Lim HY: Gemcitabine Plus Cisplatin for
Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res
Treat. 47:343–361. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Javle M, Lowery M, Shroff RT, Weiss KH,
Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S,
Macarulla T, et al: Phase II Study of BGJ398 in Patients With
FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 36:276–282.
2018. View Article : Google Scholar :
|
|
9
|
Lowery MA, Burris HA III, Janku F, Shroff
RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A,
et al: Safety and activity of ivosidenib in patients with
IDH1-mutant advanced cholangiocarcinoma: A phase 1 study. Lancet
Gastroenterol Hepatol. 4:711–720. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Akinleye A and Rasool Z: Immune checkpoint
inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol.
12:922019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi
TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH III, et
al: Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): An open-label, non-comparative, phase 1/2 dose
escalation and expansion trial. Lancet. 389:2492–2502. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu AX, Finn RS, Edeline J, Cattan S,
Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A,
et al: KEYNOTE-224 investigators: Pembrolizumab in patients with
advanced hepatocellular carcinoma previously treated with sorafenib
(KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet
Oncol. 19:940–952. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gou M, Zhang Y, Si H and Dai G: Efficacy
and safety of nivolumab for metastatic biliary tract cancer.
OncoTargets Ther. 12:861–867. 2019. View Article : Google Scholar
|
|
14
|
Ueno M, Chung HC, Nagrial A, Marabelle A,
Kelley RK, Xu L, Mahoney J, Pruitt SK and Oh D: Pembrolizumab for
advanced biliary adenocarcinoma: Results from the multicohort,
phase 2 KEYNOTE-158 study. Ann Oncol. 29(Suppl 8): pp.
viii205–viii270. 2018, View Article : Google Scholar
|
|
15
|
Xie C, Duffy AG, Mabry-Hrones D, Wood B,
Levy E, Krishnasamy V, Khan J, Wei JS, Agdashian D, Tyagi M, et al:
Tremelimumab in Combination With Microwave Ablation in Patients
With Refractory Biliary Tract Cancer. Hepatology. 69:2048–2060.
2019. View Article : Google Scholar :
|
|
16
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lapidot T, Sirard C, Vormoor J, Murdoch B,
Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA and
Dick JE: A cell initiating human acute myeloid leukaemia after
transplantation into SCID mice. Nature. 367:645–648. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamashita T and Wang XW: Cancer stem cells
in the development of liver cancer. J Clin Invest. 123:1911–1918.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Clara JA, Monge C, Yang Y and Takebe N:
Targeting signalling pathways and the immune microenvironment of
cancer stem cells - a clinical update. Nat Rev Clin Oncol.
17:204–232. 2020. View Article : Google Scholar
|
|
20
|
Lytle NK, Barber AG and Reya T: Stem cell
fate in cancer growth, progression and therapy resistance. Nat Rev
Cancer. 18:669–680. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Silver DJ, Sinyuk M, Vogelbaum MA,
Ahluwalia MS and Lathia JD: The intersection of cancer, cancer stem
cells, and the immune system: Therapeutic opportunities.
Neuro-oncol. 18:153–159. 2016. View Article : Google Scholar :
|
|
22
|
Lu W and Kang Y: Epithelial-Mesenchymal
Plasticity in Cancer Progression and Metastasis. Dev Cell.
49:361–374. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lugli A, Iezzi G, Hostettler I, Muraro MG,
Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L and Zlobec
I: Prognostic impact of the expression of putative cancer stem cell
markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.
Br J Cancer. 103:382–390. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cardinale V, Renzi A, Carpino G, Torrice
A, Bragazzi MC, Giuliante F, DeRose AM, Fraveto A, Onori P,
Napoletano C, et al: Profiles of cancer stem cell subpopulations in
cholangiocarcinomas. Am J Pathol. 185:1724–1739. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Singh SK, Clarke ID, Hide T and Dirks PB:
Cancer stem cells in nervous system tumors. Oncogene. 23:7267–7273.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Glumac PM and LeBeau AM: The role of CD133
in cancer: A concise review. Clin Transl Med. 7:182018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bhuria V, Xing J, Scholta T, Bui KC,
Nguyen MLT, Malek NP, Bozko P and Plentz RR: Hypoxia induced Sonic
Hedgehog signaling regulates cancer stemness,
epithelial-to-mesenchymal transition and invasion in
cholangiocarcinoma. Exp Cell Res. 385:1116712019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li J, Chen JN, Zeng TT, He F, Chen SP, Ma
S, Bi J, Zhu XF and Guan XY: CD133+ liver cancer stem cells resist
interferon-gamma-induced autophagy. BMC Cancer. 16:152016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shimada M, Sugimoto K, Iwahashi S,
Utsunomiya T, Morine Y, Imura S and Ikemoto T: CD133 expression is
a potential prognostic indicator in intrahepatic
cholangiocarcinoma. J Gastroenterol. 45:896–902. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mima K, Okabe H, Ishimoto T, Hayashi H,
Nakagawa S, Kuroki H, Watanabe M, Beppu T, Tamada M, Nagano O, et
al: CD44s regulates the TGF-β-mediated mesenchymal phenotype and is
associated with poor prognosis in patients with hepatocellular
carcinoma. Cancer Res. 72:3414–3423. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ishimoto T, Nagano O, Yae T, Tamada M,
Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, et al:
CD44 variant regulates redox status in cancer cells by stabilizing
the xCT subunit of system xc(-) and thereby promotes tumor growth.
Cancer Cell. 19:387–400. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Suwannakul N, Ma N, Thanan R, Pinlaor S,
Ungarreevittaya P, Midorikawa K, Hiraku Y, Oikawa S, Kawanishi S
and Murata M: Overexpression of CD44 Variant 9: A Novel Cancer Stem
Cell Marker in Human Cholangiocarcinoma in Relation to
Inflammation. Mediators Inflamm. 2018:48672342018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Morrin M and Delaney PV: CD44v6 is not
relevant in colorectal tumour progression. Int J Colorectal Dis.
17:30–36. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Coppola D, Hyacinthe M, Fu L, Cantor AB,
Karl R, Marcet J, Cooper DL, Nicosia SV and Cooper HS: CD44V6
expression in human colorectal carcinoma. Hum Pathol. 29:627–635.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vaquero J, Lobe C, Tahraoui S, Clapéron A,
Mergey M, Merabtene F, Wendum D, Coulouarn C, Housset C,
Desbois-Mouthon C, et al: The IGF2/IR/IGF1R Pathway in Tumor Cells
and Myofibroblasts Mediates Resistance to EGFR Inhibition in
Cholangiocarcinoma. Clin Cancer Res. 24:4282–4296. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie
MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, et al: Association
of reactive oxygen species levels and radioresistance in cancer
stem cells. Nature. 458:780–783. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Agrawal S, Kuvshinoff BW, Khoury T, Yu J,
Javle MM, LeVea C, Groth J, Coignet LJ and Gibbs JF: CD24
expression is an independent prognostic marker in
cholangiocarcinoma. J Gastrointest Surg. 11:445–451. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou FQ, Qi YM, Xu H, Wang QY, Gao XS and
Guo HG: Expression of EpCAM and Wnt/β-catenin in human colon
cancer. Genet Mol Res. 14:4485–4494. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yamashita T, Budhu A, Forgues M and Wang
XW: Activation of hepatic stem cell marker EpCAM by
Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res.
67:10831–10839. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sulpice L, Rayar M, Turlin B, Boucher E,
Bellaud P, Desille M, Meunier B, Clément B, Boudjema K and
Coulouarn C: Epithelial cell adhesion molecule is a prognosis
marker for intrahepatic cholangiocarcinoma. J Surg Res.
192:117–123. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vasanthakumar S, Sasikala P, Padma M,
Balachandar V, Venkatesh B and Ganesan S: EpCAM as a novel
therapeutic target for hepatocellular carcinoma. J Oncological Sci.
3:71–76. 2017. View Article : Google Scholar
|
|
43
|
Breuhahn K, Baeuerle PA, Peters M, Prang
N, Töx U, Köhne-Volland R, Dries V, Schirmacher P and Leo E:
Expression of epithelial cellular adhesion molecule (Ep-CAM) in
chronic (necro-)inflammatory liver diseases and hepatocellular
carcinoma. Hepatol Res. 34:50–56. 2006. View Article : Google Scholar
|
|
44
|
Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu
SJ, Shi RY, Hu B, Zhou J and Fan J: Circulating stem cell-like
epithelial cell adhesion molecule-positive tumor cells indicate
poor prognosis of hepatocellular carcinoma after curative
resection. Hepatology. 57:1458–1468. 2013. View Article : Google Scholar
|
|
45
|
Wang M, Xiao J, Shen M, Yahong Y, Tian R,
Zhu F, Jiang J, Du Z, Hu J, Liu W, et al: Isolation and
characterization of tumorigenic extrahepatic cholangiocarcinoma
cells with stem cell-like properties. Int J Cancer. 128:72–81.
2011. View Article : Google Scholar
|
|
46
|
Shuang ZY, Wu WC, Xu J, Lin G, Liu YC, Lao
XM, Zheng L and Li S: Transforming growth factor-β1-induced
epithelial-mesenchymal transition generates ALDH-positive cells
with stem cell properties in cholangiocarcinoma. Cancer Lett.
354:320–328. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lingala S, Cui YY, Chen X, Ruebner BH,
Qian XF, Zern MA and Wu J: Immunohistochemical staining of cancer
stem cell markers in hepatocellular carcinoma. Exp Mol Pathol.
89:27–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
You L, Guo X and Huang Y: Correlation of
Cancer Stem-Cell Markers OCT4, SOX2, and NANOG with
Clinicopathological Features and Prognosis in Operative Patients
with Rectal Cancer. Yonsei Med J. 59:35–42. 2018. View Article : Google Scholar
|
|
49
|
Zhang MX, Gan W, Jing CY, Zheng SS, Yi Y,
Zhang J, Xu X, Lin JJ, Zhang BH and Qiu SJ: High expression of Oct4
and Nanog predict poor prognosis in intrahepatic cholangiocarcinoma
patients after curative resection. J Cancer. 10:1313–1324. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Gu MJ and Jang BI: Clinicopathologic
significance of Sox2, CD44 and CD44v6 expression in intrahepatic
cholangiocarcinoma. Pathol Oncol Res. 20:655–660. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: Accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Elaimy AL and Mercurio AM: Convergence of
VEGF and YAP/TAZ signaling: Implications for angiogenesis and
cancer biology. Sci Signal. 11:pp. eaau11652018, View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Guo L and Teng L: YAP/TAZ for cancer
therapy: Opportunities and challenges (Review). Int J Oncol.
46:1444–1452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sugihara T, Isomoto H, Gores G and Smoot
R: YAP and the Hippo pathway in cholangiocarcinoma. J
Gastroenterol. 54:485–491. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kim MK, Jang JW and Bae SC: DNA binding
partners of YAP/TAZ. BMB Rep. 51:126–133. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kim HM, Jung WH and Koo JS: Expression of
Yes-associated protein (YAP) in metastatic breast cancer. Int J
Clin Exp Pathol. 8:11248–11257. 2015.PubMed/NCBI
|
|
57
|
Sugiura K, Mishima T, Takano S, Yoshitomi
H, Furukawa K, Takayashiki T, Kuboki S, Takada M, Miyazaki M and
Ohtsuka M: The Expression of Yes-Associated Protein (YAP) Maintains
Putative Cancer Stemness and Is Associated with Poor Prognosis in
Intrahepatic Cholangiocarcinoma. Am J Pathol. 189:1863–1877. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT,
Zender L, Lowe SW, Poon RT and Luk JM: Yes-associated protein is an
independent prognostic marker in hepatocellular carcinoma. Cancer.
115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lee K, Lee KB, Jung HY, Yi NJ, Lee KW, Suh
KS and Jang JJ: The correlation between poor prognosis and
increased yes-associated protein 1 expression in keratin 19
expressing hepatocellular carcinomas and cholangiocarcinomas. BMC
Cancer. 17:4412017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Liu JY, Li YH, Lin HX, Liao YJ, Mai SJ,
Liu ZW, Zhang ZL, Jiang LJ, Zhang JX, Kung HF, et al:
Overexpression of YAP 1 contributes to progressive features and
poor prognosis of human urothelial carcinoma of the bladder. BMC
Cancer. 13:3492013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Nishio M, Sugimachi K, Goto H, Wang J,
Morikawa T, Miyachi Y, Takano Y, Hikasa H, Itoh T, Suzuki SO, et
al: Dysregulated YAP1/TAZ and TGF-β signaling mediate
hepatocarcinogenesis in Mob1a/1b-deficient mice. Proc Natl Acad Sci
USA. 113:E71–E80. 2016. View Article : Google Scholar
|
|
62
|
Song H, Mak KK, Topol L, Yun K, Hu J,
Garrett L, Chen Y, Park O, Chang J, Simpson RM, et al: Mammalian
Mst1 and Mst2 kinases play essential roles in organ size control
and tumor suppression. Proc Natl Acad Sci USA. 107:1431–1436. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yamada D, Rizvi S, Razumilava N, Bronk SF,
Davila JI, Champion MD, Borad MJ, Bezerra JA, Chen X and Gores GJ:
IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an
interleukin-6-sensitive mechanism. Hepatology. 61:1627–1642. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Song S, Xie M, Scott AW, Jin J, Ma L, Dong
X, Skinner HD, Johnson RL, Ding S and Ajani JA: A Novel YAP1
Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts
Strong Antitumor Activity in Esophageal Adenocarcinoma. Mol Cancer
Ther. 17:443–454. 2018. View Article : Google Scholar
|
|
65
|
Song S, Ajani JA, Honjo S, Maru DM, Chen
Q, Scott AW, Heallen TR, Xiao L, Hofstetter WL, Weston B, et al:
Hippo coactivator YAP1 upregulates SOX9 and endows esophageal
cancer cells with stem-like properties. Cancer Res. 74:4170–4182.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ooki A, Del Carmen Rodriguez Pena M,
Marchionni L, Dinalankara W, Begum A, Hahn NM, VandenBussche CJ,
Rasheed ZA, Mao S, Netto GJ, et al: YAP1 and COX2 Coordinately
Regulate Urothelial Cancer Stem-like Cells. Cancer Res. 78:168–181.
2018. View Article : Google Scholar :
|
|
67
|
Bora-Singhal N, Nguyen J, Schaal C,
Perumal D, Singh S, Coppola D and Chellappan S: YAP1 Regulates OCT4
Activity and SOX2 Expression to Facilitate Self-Renewal and
Vascular Mimicry of Stem-Like Cells. Stem Cells. 33:1705–1718.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhu P, Wang Y, Wu J, Huang G, Liu B, Ye B,
Du Y, Gao G, Tian Y, He L, et al: LncBRM initiates YAP1 signalling
activation to drive self-renewal of liver cancer stem cells. Nat
Commun. 7:136082016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Xu Li F, Liu Y, Singh B, Zhao PK, Jin W,
Han J, Scott G, Dong AW, Huo XL, et al: YAP1-Mediated CDK6
Activation Confers Radiation Resistance in Esophageal Cancer -
Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in
Esophageal Cancer. Clin Cancer Res. 25:2264–2277. 2019. View Article : Google Scholar
|
|
70
|
Syed IS, Pedram A and Farhat WA: Role of
Sonic Hedgehog (Shh) Signaling in Bladder Cancer Stemness and
Tumorigenesis. Curr Urol Rep. 17:112016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
U.S. National Library of Medicine: A Study
Evaluating IPI-926 in Combination With Gemcitabine in Patients With
Metastatic Pancreatic Cancer. http://ClinicalTrials.govurisimpleClinicalTrials.gov
Identifier: NCT01130142. https://clinicaltrials.gov/ct2/show/NCT01130142.
Accessed May 25, 2010.
|
|
72
|
Ko AH, LoConte N, Tempero MA, Walker EJ,
Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci
DV, et al: A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog
Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Pancreas. 45:370–375. 2016. View Article : Google Scholar
|
|
73
|
Xie H, Paradise BD, Ma WW and
Fernandez-Zapico ME: Recent Advances in the Clinical Targeting of
Hedgehog/GLI Signaling in Cancer. Cells. 8:E3942019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Ranganathan P, Weaver KL and Capobianco
AJ: Notch signalling in solid tumours: A little bit of everything
but not all the time. Nat Rev Cancer. 11:338–351. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wang Z, Li Y, Banerjee S and Sarkar FH:
Emerging role of Notch in stem cells and cancer. Cancer Lett.
279:8–12. 2009. View Article : Google Scholar :
|
|
76
|
Cigliano A, Wang J, Chen X and Calvisi DF:
Role of the Notch signaling in cholangiocarcinoma. Expert Opin Ther
Targets. 21:471–483. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Fan B, Malato Y, Calvisi DF, Naqvi S,
Razumilava N, Ribback S, Gores GJ, Dombrowski F, Evert M, Chen X,
et al: Cholangiocarcinomas can originate from hepatocytes in mice.
J Clin Invest. 122:2911–2915. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Wang R, Sun Q, Wang P, Liu M, Xiong S, Luo
J, Huang H, Du Q, Geller DA and Cheng B: Notch and Wnt/β-catenin
signaling pathway play important roles in activating liver cancer
stem cells. Oncotarget. 7:5754–5768. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Schatoff EM, Leach BI and Dow LE: Wnt
Signaling and Colorectal Cancer. Curr Colorectal Cancer Rep.
13:101–110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Boulter L, Guest RV, Kendall TJ, Wilson
DH, Wojtacha D, Robson AJ, Ridgway RA, Samuel K, Van Rooijen N,
Barry ST, et al: WNT signaling drives cholangiocarcinoma growth and
can be pharmacologically inhibited. J Clin Invest. 125:1269–1285.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Park HW, Kim YC, Yu B, Moroishi T, Mo JS,
Plouffe SW, Meng Z, Lin KC, Yu FX, Alexander CM, et al: Alternative
Wnt Signaling Activates YAP/TAZ. Cell. 162:780–794. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Santoro R, Zanotto M, Simionato F,
Zecchetto C, Merz V, Cavallini C, Piro G, Sabbadini F, Boschi F,
Scarpa A and Melisi D: Modulating TAK1 expression inhibits YAP and
TAZ oncogenic functions in pancreatic cancer. Mol Cancer Ther.
19:247–257. 2020. View Article : Google Scholar
|
|
83
|
Gray JE, Infante JR, Brail LH, Simon GR,
Cooksey JF, Jones SF, Farrington DL, Yeo A, Jackson KA, Chow KH, et
al: A first-in-human phase I dose-escalation, pharmacokinetic, and
pharmacodynamic evaluation of intravenous LY2090314, a glycogen
synthase kinase 3 inhibitor, administered in combination with
pemetrexed and carboplatin. Invest New Drugs. 33:1187–1196. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
U.S. National Library of Medicine: A Study
of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer.
http://ClinicalTrials.govurisimpleClinicalTrials.gov
Identifier: NCT02232633. https://ClinicalTrials.gov/show/NCT02232633.
Accessed September 5, 2014.
|
|
85
|
Jonker DJ, Laurie SA, Cote GM, Flaherty K,
Fuchs CS, Chugh R, Smith DC, Edenfield WJ, Conkling PR, Mier JW, et
al: Phase 1 extension study of BBI503, a first-in-class cancer
stemness kinase inhibitor, in patients with advanced colorectal
cancer. J Clin Oncol. 33(Suppl 15): pp. 36152015, View Article : Google Scholar
|
|
86
|
Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang
QC, Zhang YJ, Lu R, Chen YX and Fang JY: Inhibition of JAK1,
2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces
tumor cell invasion in colorectal cancer cells. Neoplasia.
10:287–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
U.S. National Library of Medicine: A Study
of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult
Patients With Previously Treated Metastatic Colorectal Cancer.
ClinicalTrials. gov Identifier: NCT02753127. https://clinicaltrials.gov/ct2/show/NCT02753127.
Accessed April 27, 2016.
|
|
88
|
Bendell JC, Hubbard JM, O'Neil BH, Jonker
DJ, Starodub A, Peyton JD, Pitot HC, Halfdanarson TR, Nadeau BR,
Zubkus JD, et al: Phase 1b/II study of cancer stemness inhibitor
napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab
(bev) in metastatic colorectal cancer (mCRC) patients (pts). J Clin
Oncol. 35(Suppl 15): pp. 35292017, View Article : Google Scholar
|
|
89
|
Beyreis M, Gaisberger M, Jakab M,
Neureiter D, Helm K, Ritter M, Kiesslich T and Mayr C: The Cancer
Stem Cell Inhibitor Napabucasin (BBI608) Shows General Cytotoxicity
in Biliary Tract Cancer Cells and Reduces Cancer Stem Cell
Characteristics. Cancers (Basel). 11. pp. E2762019, View Article : Google Scholar
|
|
90
|
Piersma B, Bank RA and Boersema M:
Signaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge. Front Med
(Lausanne). 2:pp. 592015
|
|
91
|
Kim W, Khan SK and Yang Y: Interacting
network of Hippo, Wnt/β-catenin and Notch signaling represses liver
tumor formation. BMB Rep. 50:1–2. 2017. View Article : Google Scholar :
|
|
92
|
Rabadán MA, Cayuso J, Le Dréau G, Cruz C,
Barzi M, Pons S, Briscoe J and Martí E: Jagged2 controls the
generation of motor neuron and oligodendrocyte progenitors in the
ventral spinal cord. Cell Death Differ. 19:209–219. 2012.
View Article : Google Scholar :
|
|
93
|
He J, Sheng T, Stelter AA, Li C, Zhang X,
Sinha M, Luxon BA and Xie J: Suppressing Wnt signaling by the
hedgehog pathway through sFRP-1. J Biol Chem. 281:35598–35602.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Beier D, Hau P, Proescholdt M, Lohmeier A,
Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier
CP: CD133(+) and CD133(-) glioblastoma-derived cancer stem cells
show differential growth characteristics and molecular profiles.
Cancer Res. 67:4010–4015. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Croker AK, Goodale D, Chu J, Postenka C,
Hedley BD, Hess DA and Allan AL: High aldehyde dehydrogenase and
expression of cancer stem cell markers selects for breast cancer
cells with enhanced malignant and metastatic ability. J Cell Mol
Med. 13:2236–2252. 2009. View Article : Google Scholar
|
|
96
|
Shmelkov SV, Butler JM, Hooper AT, Hormigo
A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, et
al: CD133 expression is not restricted to stem cells, and both
CD133+ and CD133- metastatic colon cancer cells initiate tumors. J
Clin Invest. 118:2111–2120. 2008.PubMed/NCBI
|
|
97
|
Schmelzer E, Zhang L, Bruce A, Wauthier E,
Ludlow J, Yao HL, Moss N, Melhem A, McClelland R, Turner W, et al:
Human hepatic stem cells from fetal and postnatal donors. J Exp
Med. 204:1973–1987. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Sagrinati C, Netti GS, Mazzinghi B,
Lazzeri E, Liotta F, Frosali F, Ronconi E, Meini C, Gacci M,
Squecco R, et al: Isolation and characterization of multipotent
progenitor cells from the Bowman's capsule of adult human kidneys.
J Am Soc Nephrol. 17:2443–2456. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Ma S, Chan KW, Lee TK, Tang KH, Wo JY,
Zheng BJ and Guan XY: Aldehyde dehydrogenase discriminates the
CD133 liver cancer stem cell populations. Mol Cancer Res.
6:1146–1153. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Eramo A, Lotti F, Sette G, Pilozzi E,
Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De
Maria R: Identification and expansion of the tumorigenic lung
cancer stem cell population. Cell Death Differ. 15:504–514. 2008.
View Article : Google Scholar
|
|
101
|
Jaksch M, Múnera J, Bajpai R, Terskikh A
and Oshima RG: Cell cycle-dependent variation of a CD133 epitope in
human embryonic stem cell, colon cancer, and melanoma cell lines.
Cancer Res. 68:7882–7886. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Kryczek I, Liu S, Roh M, Vatan L, Szeliga
W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, et al:
Expression of aldehyde dehydrogenase and CD133 defines ovarian
cancer stem cells. Int J Cancer. 130:29–39. 2012. View Article : Google Scholar
|
|
103
|
Silva IA, Bai S, McLean K, Yang K,
Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds
RK, et al: Aldehyde dehydrogenase in combination with CD133 defines
angiogenic ovarian cancer stem cells that portend poor patient
survival. Cancer Res. 71:3991–4001. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Lardon J, Corbeil D, Huttner WB, Ling Z
and Bouwens L: Stem cell marker prominin-1/AC133 is expressed in
duct cells of the adult human pancreas. Pancreas. 36:pp. e1–e6.
2008, View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Collins AT, Berry PA, Hyde C, Stower MJ
and Maitland NJ: Prospective identification of tumorigenic prostate
cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
O'Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumour
growth in immunodeficient mice. Nature. 445:106–110. 2007.
View Article : Google Scholar
|
|
108
|
Zhou J, Wang H, Cannon V, Wolcott KM, Song
H and Yates C: Side population rather than CD133(+) cells
distinguishes enriched tumorigenicity in hTERT-immortalized primary
prostate cancer cells. Mol Cancer. 10:1122011. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Avril T, Etcheverry A, Pineau R, Obacz J,
Jegou G, Jouan F, Le Reste PJ, Hatami M, Colen RR, Carlson BL, et
al: CD90 expression controls migration and predicts dasatinib
response in glioblastoma. Clin Cancer Res. 23:7360–7374. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Yamashita T, Honda M, Nakamoto Y, Baba M,
Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, et al:
Discrete nature of EpCAM+ and CD90+ cancer stem cells in human
hepato-cellular carcinoma. Hepatology. 57:1484–1497. 2013.
View Article : Google Scholar
|
|
111
|
Wang P, Gao Q, Suo Z, Munthe E, Solberg S,
Ma L, Wang M, Westerdaal NA, Kvalheim G and Gaudernack G:
Identification and characterization of cells with cancer stem cell
properties in human primary lung cancer cell lines. PLoS One. 8:pp.
e570202013, View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Chen WC, Hsu HP, Li CY, Yang YJ, Hung YH,
Cho CY, Wang CY, Weng TY and Lai MD: Cancer stem cell marker CD90
inhibits ovarian cancer formation via β3 integrin. Int J Oncol.
49:1881–1889. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Jiang J, Zhang Y, Chuai S, Wang Z, Zheng
D, Xu F, Zhang Y, Li C, Liang Y and Chen Z: Trastuzumab (herceptin)
targets gastric cancer stem cells characterized by CD90 phenotype.
Oncogene. 31:671–682. 2012. View Article : Google Scholar
|
|
114
|
Flahaut M, Jauquier N, Chevalier N, Nardou
K, Balmas Bourloud K, Joseph JM, Barras D, Widmann C, Gross N,
Renella R, et al: Aldehyde dehydrogenase activity plays a Key role
in the aggressive phenotype of neuroblastoma. BMC Cancer.
16:7812016. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Ricardo S, Vieira AF, Gerhard R, Leitão D,
Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F and Paredes
J: Breast cancer stem cell markers CD44, CD24 and ALDH1: expression
distribution within intrinsic molecular subtype. J Clin Pathol.
11:937–946. 2011. View Article : Google Scholar
|
|
116
|
Feng H and Liu Y, Bian X, Zhou F and Liu
Y: ALDH1A3 affects colon cancer in vitro proliferation and invasion
depending on CXCR4 status. Br J Cancer. 118:224–232. 2018.
View Article : Google Scholar :
|
|
117
|
Khorrami S, Zavaran Hosseini A, Mowla SJ
and Malekzadeh R: Verification of ALDH Activity as a Biomarker in
Colon Cancer Stem Cells-Derived HT-29 Cell Line. Iran J Cancer
Prev. 8:pp. e34462015, View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Moreb JS, Baker HV, Chang LJ, Amaya M,
Lopez MC, Ostmark B and Chou W: ALDH isozymes downregulation
affects cell growth, cell motility and gene expression in lung
cancer cells. Mol Cancer. 7:872008. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Yan J, De Melo J, Cutz JC, Aziz T and Tang
D: Aldehyde dehydrogenase 3A1 associates with prostate
tumorigenesis. Br J Cancer. 110:2593–2603. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Li W, Ma H, Zhang J, Zhu L, Wang C and
Yang Y: Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem
cell markers in tumorigenesis and metastasis. Sci Rep. 7:138562017.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Luo Y, Dallaglio K, Chen Y, Robinson WA,
Robinson SE, McCarter MD, Wang J, Gonzalez R, Thompson DC, Norris
DA, et al: ALDH1A isozymes are markers of human melanoma stem cells
and potential therapeutic targets. Stem Cells. 30:2100–2113. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Mueller MT, Hermann PC, Witthauer J,
Rubio-Viqueira B, Leicht SF, Huber S, Ellwart JW, Mustafa M,
Bartenstein P, D'Haese JG, et al: Combined targeted treatment to
eliminate tumorigenic cancer stem cells in human pancreatic cancer.
Gastroenterology. 137:1102–1113. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Pietras A, Katz AM, Ekström EJ, Wee B,
Halliday JJ, Pitter KL, Werbeck JL, Amankulor NM, Huse JT and
Holland EC: Osteopontin-CD44 signaling in the glioma perivascular
niche enhances cancer stem cell phenotypes and promotes aggressive
tumor growth. Cell Stem Cell. 14:357–369. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Fu J, Yang QY, Sai K, Chen FR, Pang JC, Ng
HK, Kwan AL and Chen ZP: TGM2 inhibition attenuates ID1 expression
in CD44-high glioma-initiating cells. Neuro-oncol. 15:1353–1365.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Todaro M, Gaggianesi M, Catalano V,
Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S,
Cocorullo G, et al: CD44v6 is a marker of constitutive and
reprogrammed cancer stem cells driving colon cancer metastasis.
Cell Stem Cell. 14:342–356. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Paradis V, Ferlicot S, Ghannam E, Zeimoura
L, Blanchet P, Eschwége P, Jardin A, Benoît G and Bedossa P: CD44
is an independent prognostic factor in conventional renal cell
carcinomas. J Urol. 161:1984–1987. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J and
Li J: Cancer stem/progenitor cells are highly enriched in
CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer.
126:2067–2078. 2010.
|
|
128
|
He QZ, Luo XZ, Wang K, Zhou Q, Ao H, Yang
Y, Li SX, Li Y, Zhu HT and Duan T: Isolation and characterization
of cancer stem cells from high-grade serous ovarian carcinomas.
Cell Physiol Biochem. 33:173–184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Patrawala L, Calhoun T,
Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra
D, Zhou J, Claypool K, et al: Highly purified CD44+ prostate cancer
cells from xenograft human tumors are enriched in tumorigenic and
metastatic progenitor cells. Oncogene. 25:1696–1708. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y,
Uraoka N, Anami K, Sentani K, Oue N and Yasui W: Expression of
cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and
lymph node metastasis of gastric cancer. Pathol Int. 62:pp.
112–119. 2012, View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Kimura Y, Goi T, Nakazawa T, Hirono Y,
Katayama K, Urano T and Yamaguchi A: CD44variant exon 9 plays an
important role in colon cancer initiating cells. Oncotarget.
4:785–791. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Yae T, Tsuchihashi K, Ishimoto T, Motohara
T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H,
et al: Alternative splicing of CD44 mRNA by ESRP1 enhances lung
colonization of metastatic cancer cell. Nat Commun. 3:8832012.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Takaishi S, Okumura T, Tu S, Wang SS,
Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC:
Identification of gastric cancer stem cells using the cell surface
marker CD44. Stem Cells. 27:1006–1020. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Wang T, Gantier MP, Xiang D, Bean AG,
Bruce M, Zhou SF, Khasraw M, Ward A, Wang L, Wei MQ, et al: EpCAM
aptamer-mediated survivin silencing sensitized cancer stem cells to
doxorubicin in a breast cancer model. Theranostics. 5:14562015.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Münz M, Kieu C, Mack B, Schmitt B, Zeidler
R and Gires O: The carcinoma-associated antigen EpCAM upregulates
c-myc and induces cell proliferation. Oncogene. 23:57482004.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Yeung TM, Gandhi SC, Wilding JL, Muschel R
and Bodmer WF: Cancer stem cells from colorectal cancer-derived
cell lines. Proc Natl Acad Sci USA. 107:3722–3727. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Lee TK, Castilho A, Cheung VC, Tang KH, Ma
S and Ng IO: CD24(+) liver tumor-initiating cells drive
self-renewal and tumor initiation through STAT3-mediated NANOG
regulation. Cell Stem Cell. 9:50–63. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Gangemi RM, Griffero F, Marubbi D, Perera
M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A and Corte G:
SOX2 silencing in glioblastoma tumor-initiating cells causes stop
of proliferation and loss of tumorigenicity. Stem Cells. 27:40–48.
2009. View Article : Google Scholar
|
|
140
|
Chen Y, Shi L, Zhang L, Li R, Liang J, Yu
W, Sun L, Yang X, Wang Y, Zhang Y, et al: The molecular mechanism
governing the oncogenic potential of SOX2 in breast cancer. J Biol
Chem. 283:17969–17978. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Chou YT, Lee CC, Hsiao SH, Lin SE, Lin SC,
Chung CH, Chung CH, Kao YR, Wang YH, Chen CT, et al: The emerging
role of SOX2 in cell proliferation and survival and its crosstalk
with oncogenic signaling in lung cancer. Stem Cells. 31:2607–2619.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Higgins DM, Wang R, Milligan B, Schroeder
M, Carlson B, Pokorny J, Cheshier SH, Meyer FB, Weissman IL,
Sarkaria JN, et al: Brain tumor stem cell multipotency correlates
with nanog expression and extent of passaging in human glioblastoma
xenografts. Oncotarget. 4:792–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Jeter CR, Badeaux M, Choy G, Chandra D,
Patrawala L, Liu C, Calhoun-Davis T, Zaehres H, Daley GQ and Tang
DG: Functional evidence that the self-renewal gene NANOG regulates
human tumor development. Stem Cells. 27:993–1005. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Hoei-Hansen CE, Almstrup K, Nielsen JE,
Brask Sonne S, Graem N, Skakkebaek NE, Leffers H and Rajpert-De
Meyts E: Stem cell pluripotency factor NANOG is expressed in human
fetal gonocytes, testicular carcinoma in situ and germ cell
tumours. Histopathology. 47:48–56. 2005. View Article : Google Scholar : PubMed/NCBI
|
